S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
NASDAQ:LIXT

Lixte Biotechnology News Headlines

$1.63
+0.03 (+1.88%)
(As of 11/30/2021 04:00 PM ET)
Add
Compare
Today's Range
$1.61
$1.68
50-Day Range
$1.60
$2.32
52-Week Range
$1.56
$7.19
Volume
27,249 shs
Average Volume
463,228 shs
Market Capitalization
$22.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-1.41

Media Mentions By Week



Lixte Biotechnology Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LIXT
News Sentiment

1.00

0.27

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LIXT Articles
This Week

1

0

LIXT Articles
Average Week

Get Lixte Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.

Lixte Biotechnology (NASDAQ:LIXT) News Headlines Today

SourceHeadline
finance.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS
finance.yahoo.com - November 22 at 9:41 AM
MarketBeat logoLixte Biotechnology (NASDAQ:LIXT) Trading Down 3.9%
americanbankingnews.com - November 18 at 12:56 AM
finance.yahoo.com logoLixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
finance.yahoo.com - October 20 at 3:20 PM
finance.yahoo.com logoLixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
finance.yahoo.com - October 13 at 9:47 AM
nasdaq.com logoBullish insiders at Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) loaded up on US$1.3m of stock earlier this year
nasdaq.com - September 26 at 1:01 PM
finance.yahoo.com logoWe Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth
finance.yahoo.com - September 24 at 1:41 PM
nasdaq.com logoLixte Biotechnology Holdings Inc Shares Fall 1.5% Below Previous 52-Week Low - Market Mover
nasdaq.com - September 22 at 9:49 AM
finance.yahoo.com logoLixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
finance.yahoo.com - August 17 at 5:00 PM
finance.yahoo.com logoLixte's LB-100 Blocks Behavioral Sensitization In Animal Models
finance.yahoo.com - August 17 at 5:00 PM
barrons.com logoLixte Biotechnology Holdings Inc.
barrons.com - August 8 at 11:44 PM
msn.com logoLixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer
msn.com - August 3 at 4:10 PM
marketwatch.com logoLixte Biotechnology Shares Rise 31% on Positive Data for Lung Cancer Treatment
marketwatch.com - August 3 at 4:10 PM
finance.yahoo.com logoLIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
finance.yahoo.com - August 3 at 11:10 AM
finance.yahoo.com logoLIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
finance.yahoo.com - July 22 at 12:52 PM
finance.yahoo.com logoLixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
finance.yahoo.com - July 13 at 1:37 PM
finance.yahoo.com logoLixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
finance.yahoo.com - July 7 at 9:44 AM
nasdaq.com logoCompanies Like Lixte Biotechnology Holdings (NASDAQ:LIXT) Are In A Position To Invest In Growth
nasdaq.com - June 28 at 12:33 PM
finance.yahoo.com logoNeed To Know: Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Insiders Have Been Buying Shares
finance.yahoo.com - June 26 at 1:11 PM
benzinga.com logoA Breakthrough in Targeted Cancer Therapy: Lixte Biotechnology Clinical Stage Compound LB-100
benzinga.com - June 3 at 9:54 AM
finance.yahoo.com logoLixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
finance.yahoo.com - June 2 at 1:19 PM
ca.finance.yahoo.com logoSanta Monica Partners Lp Buys Boeing Co, Lixte Biotech Holdings Inc
ca.finance.yahoo.com - May 19 at 11:49 PM
finance.yahoo.com logoLIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
finance.yahoo.com - May 12 at 1:09 PM
marketwatch.com logoProtein Phosphatase 2A Market Size 2021: Impact of Covid-19, Top Manufacturers, Regional Outlook, Competitive Strategies and Forecasts 2027
marketwatch.com - May 8 at 8:26 AM
finance.yahoo.com logoLixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
finance.yahoo.com - May 4 at 8:31 PM
finance.yahoo.com logoLixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
finance.yahoo.com - April 28 at 9:43 AM
finance.yahoo.com logoLixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24
finance.yahoo.com - March 17 at 12:48 PM
baystreet.ca logoLixte Jumps on Direct Offering
baystreet.ca - March 15 at 1:34 PM
finance.yahoo.com logoLixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
finance.yahoo.com - March 3 at 12:47 PM
markets.businessinsider.com logoGuardion Health Sciences Inc Registered Shs Stock , GHSI
markets.businessinsider.com - March 3 at 2:46 AM
finance.yahoo.com logoLixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
finance.yahoo.com - March 2 at 11:44 AM
finance.yahoo.com logoLixte Biotechnology Announces $4.19 Million Registered Direct Offering
finance.yahoo.com - March 1 at 12:43 PM
benzinga.com logoLixte Biotech shares are trading higher. Not seeing any company-specific news to justify the price action.
benzinga.com - February 28 at 2:57 PM
nasdaq.com logoAre These The Top Biotech Stocks To Buy In March? 4 Names To Consider
nasdaq.com - February 26 at 7:57 PM
markets.businessinsider.com logoStock Alert: Lixte Biotechnology Up 55%
markets.businessinsider.com - February 26 at 2:56 PM
finance.yahoo.com logoWe Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Needs To Drive Business Growth Carefully
finance.yahoo.com - February 25 at 12:47 PM
finance.yahoo.com logoLixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - February 24 at 9:49 AM
seekingalpha.com logoLixte Biotech's lead candidate to be tested in small cell lung cancer patients
seekingalpha.com - January 27 at 6:37 PM
nasdaq.com logoStock Alert: Lixte Biotechnology Adds 15% Following Deal With City Of Hope
nasdaq.com - January 19 at 6:56 PM
bloomberg.com logoLixte Biotechnology Holdings Inc
bloomberg.com - December 23 at 8:48 PM
finance.yahoo.com logoLixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
finance.yahoo.com - December 23 at 10:48 AM
finance.yahoo.com logoLixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
finance.yahoo.com - December 23 at 10:48 AM
finance.yahoo.com logoThe Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome
finance.yahoo.com - December 23 at 10:48 AM
finance.yahoo.com logoLixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
finance.yahoo.com - December 23 at 10:48 AM
finance.yahoo.com logoWestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)
finance.yahoo.com - December 23 at 10:48 AM
finance.yahoo.com logoLixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
finance.yahoo.com - December 23 at 10:48 AM
finance.yahoo.com logoWallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.
finance.yahoo.com - December 23 at 10:48 AM
finance.yahoo.com logoLixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors
finance.yahoo.com - March 16 at 9:50 AM
finance.yahoo.com logoLixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder
finance.yahoo.com - March 16 at 9:50 AM
finance.yahoo.com logoFirst Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome
finance.yahoo.com - March 16 at 9:50 AM
finance.yahoo.com logoThe Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
finance.yahoo.com - March 16 at 9:50 AM
Get Lixte Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.